Recent Finacing
Recent Raise
MYR GmbH (Burgwedel, Germany) develops Myrcludex, a viral entry inhibitor for chronic hepatitis B and D, holding worldwide exclusive rights and collaborating with University Clinic Heidelberg.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor